

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**GUIDANCE EXECUTIVE (GE)**

**Consideration of consultation responses on review proposal**

**Review of TA127; Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis**

This guidance was issued August 2007 with a review date of June 2010

**Background**

At the GE meeting 29 June 2010 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

<b>Proposal put to consultees:</b>	A review of the guidance should be deferred until the completion of the SURPASS trial which is expected to be in 2013. At this point the review of TA127 and TA32 should be considered together. That we consult on the proposal.
------------------------------------	---

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

<b>Recommendation post consultation:</b>	A review of the guidance should be deferred until the completion of the SURPASS trial which is expected to be in 2013. At this point the review of TA127 and TA32 should be considered together.
--	--

<b>Respondent</b>	<b>Respons</b>	<b>Details</b>	<b>Comment from Technology</b>
-------------------	----------------	----------------	--------------------------------

	<b>e to proposal</b>		<b>Appraisal</b>
MS Trust	Agree	Happy with your proposed plan of action	Agree
Multiple Sclerosis Resource Centre (MSRC)	Agree	Happy for NICE to proceed as stated	Agree
NHS Quality Improvement Scotland	No comment	No comment to make on the proposal	N/A
Novartis Pharmaceuticals	Agree	Agree with the proposal	Agree
Welsh Assembly Government	No comment	No comment to submit at this stage	N/A

**No response received from:**

<u>Manufacturers/sponsors</u>	<u>General</u>
<ul style="list-style-type: none"> <li>• Biogen Idec and Elan Pharma International (natalizumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Brain and Spine Foundation</li> <li>• Chinese National Healthy Living Centre</li> <li>• Connect</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> </ul>	<ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> </ul>

- Leonard Cheshire Disability
- Multiple Sclerosis National Therapy Centres
- Multiple Sclerosis Society
- Muslim Council of Britain
- Muslim Health Network
- Neurological Alliance
- Neurosupport
- Royal Association for Disability and Rehabilitation (RADAR)
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Sue Ryder Care

Professional groups

- Association of British Neurologists
- British Association for Services to the Elderly
- British Geriatrics Society
- British Neuropathological Society
- British Society of Rehabilitative Medicine
- Chartered Society of Physiotherapy
- Institute of Neurology
- Primary Care Neurology Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Therapists in MS (TIMS)
- United Kingdom Clinical Pharmacy Association

- Public Health Wales NHS Trust
- Scottish Medicines Consortium

Comparator manufacturers

- Bayer (Interferon beta-1b)
- Biogen Idec (Interferon beta-1a)
- Merck Serono (Interferon beta-1a)
- sanofi Aventis (glatiramer acetate)

Relevant research groups

- British Neurological Research Trust
- MRC Clinical Trials Unit
- National Institute for Health Research
- Neurosciences Research Unit, University of Liverpool
- Policy Research Institute on Ageing and Ethnicity
- Research Institute for the Care of Older People

Assessment Group

- National Institute for Health Research Health Technology Assessment

Associated Guideline Group

- National Clinical Guideline Centre

Associated Public Health Groups

- (none)

- |   |  |
|---|--|
| <ul style="list-style-type: none"><li>• United Kingdom Multiple Sclerosis Specialist Nurse Association (UKMSSNA)</li></ul> <p><u>Others</u></p> <ul style="list-style-type: none"><li>• Department of Health</li><li>• East and North Hertfordshire NHS Trust</li><li>• NHS Bradford and Airedale</li></ul> |  |
|---|--|



**GE paper sign-off:** Helen Chung 18<sup>th</sup> November 2010

**Contributors to this paper:**

Information Specialist: Mike Raynor  
Technical Lead: Scott Goulden/Helen Tucker  
Technical Adviser: Zoe Charles  
Project Manager: Andrew Harding